Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2015-001750-15-GR
EUCTR2015-001750-15-GRActive, not recruitingPhase 1

A double-blind, randomised, placebo-controlled trial evaluating the effect of BI 655064 administered as sub-cutaneous injections, on renal response after one year of treatment, in patients with active lupus nephritis - POC in lupus nephritis

Boehringer Ingelheim Ellas SA0 sites160 target enrollmentStarted: April 18, 2016Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Sponsor
Enrollment
160
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •males and females 18-70 years. Women of childbearing potential* must be ready and able to use simultaneously two highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. The contraception should be used before starting MMF therapy and the study drug, during the treatment and until 6 weeks after stopping MMF and the study drug. Sexually active men must be ready to use condoms during treatment with MMF and for at least 90 days after cessation of MMF treatment.
  • •Diagnosis of systemic lupus erythematosus (SLE) by ACR criteria 1997, at least 4 criteria must be documented, one of which must be a positive anti-dsDNA antibody at screening or around time of start of induction therapy
  • •Lupus Nephritis Class III or IV (ISN/RPS 2003 classification) with either active or active/chronic disease, co-existing class V permitted, proven by renal biopsy within 3 months prior to screening or during screening if induction therapy has not yet been started
  • •Active renal disease evidenced by proteinuria >= 1.0 g/day (Uprot/ucrea >= 100 mg/mmol)
  • •Signed and dated written informed consent
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range: 0
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 109
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 11

Exclusion Criteria

  • •clinically significant current other renal disease
  • •GFR<30ml/min/1.73m²
  • •Acute presence of Oliguria (<500 mL/day)
  • •dialysis within 12m of screening
  • •Antiphospholipid syndrom
  • •diabetes mellitus poorly controlled or known diabethic retinopathy or nephropathy
  • •Evidence of current or previous clinically significant disease, medical condition or finding in the medical examination that in the investigator's opinion would compromise the safety of the patient or the quality of the data
  • •Live vaccination within 6 weeks before randomisation
  • •Any induction therapy for LN within the last 6 months prior to randomisation except induction with MMF and high dose steroids tarted within 4 weeks prior to randomisation
  • •Treatment with any biologic B-cell depleting therapy (e.g. anti-CD20, anti-CD22, anti-BLyS) within 12 months prior to randomisation
  • •Treatment with abatacept within 12 months prior to randomisation
  • •Treatment with tacrolimus or cyclosporin within 4 weeks prior to randomisation
  • •Treatment with cyclophosphamid within 6 months prior to randomisation
  • •Treatment with investigational drug within 6 months or 5 half-lives, whichever is greater before randomisation
  • •Contraindication for MMF or corticosteroids
  • •Chronic or relevant acute infections, including but not limited to HIV, Hepatitis B and C and tuberculosis (including a history of clinical TB and/or a positive QuantiFERON TB-Gold test
  • •Any active or suspected malignancy or history of documented malignancy within the last 5 years before screening, except appropriately treated carcinoma in situ and treated basal cell carcinoma.
  • •Patients unable to comply with the protocol in the investigator¿s opinion.
  • •Alcohol abuse in the opinion of the investigator or active drug abuse .
  • •Women who are pregnant, nursing, or who plan to become pregnant while in the trial
  • •Impaired hepatic function, defined as serum AST/ALT, bilirubin or alkaline phosphatase levels > 2 x ULN

Investigators

Sponsor
Boehringer Ingelheim Ellas SA

Similar Trials

Recruiting
Phase 3
Melatonin supplementation effect on the Induction of labour rates in first-time MothErs:The MyTIME TrialInduction of labourReproductive Health and Childbirth - Childbirth and postnatal care
ACTRN12623000502639Curtin University530
Active, not recruiting
Not Applicable
A double-blind, randomised, placebo-controlled trial confirming the efficacy of intranasal fentanyl titrated to 50, 100 or 200 µg with an open long-term safety follow-up in cancer patients with breakthrough paiBreakthrough PainMedDRA version: 8.1Level: PTClassification code 10064556
EUCTR2005-002348-24-DKycomed Danmark ApS200
Active, not recruiting
Phase 1
Efficacy and safety of BI 655064 in patients with Lupus Nephritis
EUCTR2015-001750-15-ITBOEHRINGER-INGELHEIM ITALIA S.P.A.160
Active, not recruiting
Phase 1
Efficacy and safety of BI 655064 in patients with Lupus Nephritisupus NephritisMedDRA version: 20.1Level: PTClassification code 10025140Term: Lupus nephritisSystem Organ Class: 10038359 - Renal and urinary disorders
EUCTR2015-001750-15-ATBoehringer Ingelheim RCV GmbH & Co KG160
Active, not recruiting
Not Applicable
A double-blind, randomised, placebo-controlled trial confirming the efficacy of intranasal fentanyl titrated to 50, 100 or 200 µg with an open long-term safety follow-up in cancer patients with breakthrough paiBreakthrough PainMedDRA version: 8.1Level: PTClassification code 10064556
EUCTR2005-002348-24-DEycomed Danmark ApS200
Efficacy and safety of BI 655064 in... | Clinical Trial